

March 23, 2018

Via EDGAR Transmission

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor

**Re: Homology Medicines, Inc.
Registration Statement on Form S-1
Filed March 2, 2018
Registration No. 333-223409**

Dear Mr. Gabor:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 27, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Homology Medicines, Inc. (the "Company") or its counsel may request via telephone call to the staff. Please contact Wesley Holmes of Latham & Watkins LLP, counsel to the Company, at (212) 906-1366, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

Sincerely yours,

Homology Medicines, Inc.

By: /s/ Arthur O. Tzianabos, Ph.D.

Arthur O. Tzianabos, Ph.D.

President and Chief Executive Officer

cc: Peter N. Handrinos, Esq.
Wesley C. Holmes, Esq.